Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemoth...
Original Article: Merck, Pfizer combo treatment boosts kidney cancer survival